FME.DE - Fresenius Medical Care AG & Co. KGaA

XETRA - XETRA Delayed price. Currency in EUR
71.34
+1.06 (+1.51%)
As of 3:34PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close70.28
Open71.62
Bid71.28 x 38700
Ask71.36 x 105300
Day's range70.96 - 72.78
52-week range55.44 - 91.74
Volume519,101
Avg. volume788,265
Market cap21.733B
Beta (3Y monthly)1.28
PE ratio (TTM)11.11
EPS (TTM)6.42
Earnings date30 Jul 2019
Forward dividend & yield1.17 (1.66%)
Ex-dividend date2019-05-17
1y target est80.61
  • Is Cara Therapeutics a Buy Now?
    Motley Fool18 days ago

    Is Cara Therapeutics a Buy Now?

    A pivotal trial for the company's lead candidate was an unequivocal success.

  • Reuters2 months ago

    Fresenius makes solid start to year after turbulent 2018

    Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.

  • MarketWatch3 months ago

    Fresenius Medical Care to pay $231 million to settle bribery charges

    The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA , a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC. Fresenius was found to have violated the Foreign Corrupt Practices Act by falsifying documents as well as contracts and funneling bribes through third-party intermediaries. FMC paid nearly $30 million in bribes to government officials and others to procure business, the company said. "By engaging in widespread bribery schemes across multiple countries, the company prioritized profits over compliance in its dealings with foreign government officials," said Tracy Price, deputy chief of the SEC Enforcement Division's FCPA Unit, in a statement.

  • How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?
    Simply Wall St.3 months ago

    How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?

    If you want to know who really controls Fresenius Medical Care AG & Co. KGaA (ETR:FME), then you'll have to look at the makeup of its share registry. Large companiesRead More...

  • Reuters4 months ago

    U.S. seeks to cut dialysis costs with more home care versus clinics

    The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending. The U.S. Centers for Medicare and Medicaid Services (CMS), which provides Medicare health benefits to more than 55 million Americans, is looking at a trial payment design that would improve care in the early stages of kidney disease, increase access to kidney transplants and favor home dialysis over clinic-based treatment, CMS head Seema Verma told Reuters in an interview.

  • Reuters4 months ago

    Deals of the day-Mergers and acquisitions

    (Adds Ophir Energy, Alitalia, Bristol-Myers Squibb, Cemex, Tilray, Magellan Health, Verus Petroleum, Owens & Minor; Updates Bank Audi, Sainsbury) Feb 20 (Reuters) - The following bids, mergers, acquisitions ...

  • Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript

    FMS earnings call for the period ending December 31, 2018.

  • FMC expects NxStage deal to close in next couple of days
    Reuters4 months ago

    FMC expects NxStage deal to close in next couple of days

    Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.

  • Reuters - UK Focus4 months ago

    Sainsbury's, Swedbank sink while trade talk progress boosts European shares

    Encouraging signs from trade talks between the world's two biggest economies helped boost European shares on Wednesday while the threat of a blocked merger deal sank Sainsbury's shares. Germany's trade-sensitive ...

  • Should We Be Delighted With Fresenius Medical Care AG & Co. KGaA’s (ETR:FME) ROE Of 18%?
    Simply Wall St.4 months ago

    Should We Be Delighted With Fresenius Medical Care AG & Co. KGaA’s (ETR:FME) ROE Of 18%?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While some investors are already well versed in financial metricsRead More...

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool5 months ago

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Both of these biotech companies are getting close to achieving commercial successes.

  • A Look At The Fair Value Of Fresenius Medical Care AG & Co. KGaA (ETR:FME)
    Simply Wall St.5 months ago

    A Look At The Fair Value Of Fresenius Medical Care AG & Co. KGaA (ETR:FME)

    Does the January share price for Fresenius Medical Care AG & Co. KGaA (ETR:FME) reflect it's really worth? Today, I will calculate the stock's intrinsic value by taking the expected Read More...

  • Reuters5 months ago

    FMC extends deadline for NxStage deal until Aug. 6 due to U.S. government shutdown

    Germany's Fresenius Medical Care (FMC) said on Tuesday it had agreed to extend the deadline for its planned $2 billion takeover of U.S. home dialysis equipment maker NxStage Medical Inc until August 6. FMC said the extension had been agreed due to the recent U.S. government shutdown which interrupted the Federal Trade Commission's (FTC) ability to review the transaction.

  • EQS Group6 months ago

    Fresenius Medical Care awaiting U.S. Federal Trade Commission decision on NxStage Medical acquisition

    DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous28.12.2018 / 22:18 The issuer is solely responsible for the content of this announcement.Fresenius Medical Care, the world's largest provider of dialysis products and services, is still in the process of seeking approval by the U.S. Federal Trade Commission (FTC) for its acquisition of NxStage Medical, Inc. ("NxStage") and therefore now expects the transaction to close in early 2019. ...

  • Simply Wall St.6 months ago

    Fresenius Medical Care AG & Co. KGaA (ETR:FME): Time For A Financial Health Check

    Investors pursuing a solid, dependable stock investment can often be led to Fresenius Medical Care AG & Co. KGaA (ETR:FME), a large-cap worth €18b. Big corporations are much sought after Read More...

  • EQS Group6 months ago

    Fresenius Medical Care AG & Co. KGaA: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

    Fresenius Medical Care AG & Co. KGaA / Total Voting Rights Announcement12.12.2018 / 16:10Total Voting Rights Announcement transmitted by DGAP - a service of EQSGroup AG.The issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------Publication of total number of voting rights1. Details of issuer Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany2. Type of capital measure Type of capital measure Date of status / date of effect X Conditional capital increase (Sec. 41 5 Dec 2018 ...

  • EQS Group6 months ago

    Fresenius Medical Care gives early preliminary indicative guidance for 2019

    DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast06.12.2018 / 23:16 The issuer is solely responsible for the content of this announcement.

  • EQS Group6 months ago

    Fresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 2019

    Fresenius Medical Care AG & Co. KGaA / Key word(s): ForecastFresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 201906-Dec-2018 / 22:35 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Fresenius Medical Care, the world's largest provider of dialysis products and services, has decided to update the market early on its indicative preliminary assumptions for the business development in 2019. ...

  • EQS Group6 months ago

    Fresenius Medical Care announces acquisition of renal hospitals and dialysis centers in China

    DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Acquisition05.12.2018 / 11:35 The issuer is solely responsible for the content of this announcement.

  • Why Cara Therapeutics Is Up 50% in 2018
    Motley Fool7 months ago

    Why Cara Therapeutics Is Up 50% in 2018

    Three key reasons behind this clinical-stage biotech's impressive year-to-date performance.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes